This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Oct 22;172(19):1521-2; author reply 1522-3.

doi: 10.1001/archinternmed.2012.4386.

What is more valuable: fenofibrate patents or fenofibrate clinical outcomes?

PMID: 23090194
DOI: 10.1001/archinternmed.2012.4386

Comment

What is more valuable: fenofibrate patents or fenofibrate clinical outcomes?

Joel W Hay. Arch Intern Med. 2012.

. 2012 Oct 22;172(19):1521-2; author reply 1522-3.

doi: 10.1001/archinternmed.2012.4386.

Author

PMID: 23090194
DOI: 10.1001/archinternmed.2012.4386

No abstract available

PubMed Disclaimer

Comment on

Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise.
Downing NS, Ross JS, Jackevicius CA, Krumholz HM. Downing NS, et al. Arch Intern Med. 2012 May 14;172(9):724-30. doi: 10.1001/archinternmed.2012.187. Arch Intern Med. 2012. PMID: 22493409 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information